BLOCK LISTING SIX MONTHLY RETURN

May 23, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)

Name of applicant: Shire plc
Name of scheme: Shire Sharesave Scheme
Period of return: From: November 23, 2016 To: May 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 184,611
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 17,079
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 167,532
Name of applicant: Shire plc
Name of scheme: Shire Portfolio Share Plan
Period of return: From: November 23, 2016 To: May 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 769,615
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 405,083
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 364,532
Name of applicant: Shire plc
Name of scheme: Shire Employee Stock Purchase Plan
Period of return: From: November 23, 2016 To: May 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 244,057
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 6,359
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 237,698
Name of applicant: Shire plc
Name of scheme: Shire Long Term Incentive Plan 2015
Period of return: From: November 23, 2016 To: May 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 2,836,412
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 145,740
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 2,690,672
Name of applicant: Shire plc
Name of scheme: Shire Global Employee Stock Purchase Plan
Period of return: From: November 23, 2016 To: May 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 1,604,243
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 3,400
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 1,600,843
Name of applicant: Shire plc
Name of scheme: Baxalta Exchange Awards
Period of return: From: November 23, 2016 To: May 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 20,488,204
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 2,492,337
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 17,995,867
Name of contact: Sarah Rixon, Company Secretarial Assistant
Telephone number of contact: 01256 894000

For further information please contact:

Investor Relations
Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 1256 894874
Media
Lisa Adler lisa.adler@shire.com +1-617 588 8607
Debbi Ford debbi.ford@shire.com +1 617 949 9083

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com

Shire plc published this content on 23 May 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 23 May 2017 11:30:24 UTC.

Original documenthttp://otp.investis.com/clients/uk/shire/rns1/regulatory-story.aspx?cid=1027&newsid=876111

Public permalinkhttp://www.publicnow.com/view/71BE19F767AF09F565C057AFC2D16206642F015C